Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 1.00 |
| ▸ | AKT2 | P31751 | 13/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 13/20 | 0.70 |
| ▸ | AKT3 | Q9Y243 | 11/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.63 |
| ▸ | GSK3B | P49841 | 1/20 | 0.63 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.63 |
| ▸ | LATS1 | O95835 | 1/20 | 0.63 |
| ▸ | PRKCB | P05771 | 1/20 | 0.63 |
| ▸ | RET | P07949 | 1/20 | 0.63 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.63 |
| ▸ | PRKCA | P17252 | 1/20 | 0.63 |
| ▸ | PRKACA | P17612 | 1/20 | 0.63 |
| ▸ | PRKACB | P22694 | 1/20 | 0.63 |
| ▸ | GRK2 | P25098 | 1/20 | 0.63 |
| ▸ | CLK1 | P49759 | 1/20 | 0.63 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1973100 | 0.86 | AKT1 (0.76) | AKT1AKT2ROCK2AKT3KCNH2 | |
| SCHEMBL1001031 | 0.83 | AKT2 (1.00) | AKT1AKT2ROCK2AKT3KCNH2 | |
| SCHEMBL390673 | 0.80 | AKT1 (1.00) | AKT1AKT2ROCK2AKT3KCNH2 | |
| SCHEMBL387281 | 0.80 | AKT1 (1.00) | AKT1AKT2ROCK2AKT3KCNH2 | |
| SCHEMBL391158 | 0.80 | AKT1 (1.00) | AKT1AKT2ROCK2AKT3KCNH2 | |
| SCHEMBL390582 | 0.80 | AKT1 (1.00) | AKT1AKT2ROCK2AKT3KCNH2 | |
| SCHEMBL390590 | 0.80 | AKT1 (1.00) | AKT1AKT2ROCK2AKT3KCNH2 | |
| SCHEMBL390992 | 0.80 | AKT1 (1.00) | AKT1AKT2ROCK2AKT3KCNH2 | |
| SCHEMBL390332 | 0.80 | AKT1 (1.00) | AKT1AKT2ROCK2AKT3KCNH2 | |
| SCHEMBL386815 | 0.80 | AKT1 (1.00) | AKT1AKT2ROCK2AKT3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812004-B1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2011-06-22 | — | — | EP | claimed |
| EP-3719018-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2025-08-27 | — | — | EP | disclosed |
| EP-3421471-B1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2021-05-26 | — | — | EP | disclosed |
| EP-3719018-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Ltd (GB) | 2020-10-07 | — | — | EP | disclosed |
| EP-3421471-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2019-01-02 | — | — | EP | disclosed |
| EP-2272517-B2 | ORTHO -CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2017-09-20 | — | — | EP | disclosed |
| US-9006430-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein | ASTEX THERAPEUTICS LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| US-9006430-B2 | Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein | ASTEX THERAPEUTICS LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| US-20140303177-A1 | ORTHO-CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G., PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-09 | — | — | US | disclosed |
| US-20140303177-A1 | ORTHO-CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G., PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2014-10-09 | — | — | US | disclosed |
| CN-101489559-B | Purine and deazapurine derivatives as pharmaceutical compounds | ASTEX THERAPEUTICS LTD | 2012-08-15 | — | — | CN | disclosed |
| EP-1812004-B1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2011-06-22 | — | — | EP | disclosed |
| EP-1812004-B1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2011-06-22 | — | — | EP | disclosed |
| EP-2272517-A1 | Ortho-condensed pyridine and pyrimidine derivatives ( e.g. purines ) as protein kinases inhibitors | Astex Therapeutics Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| EP-2272517-A1 | Ortho-condensed pyridine and pyrimidine derivatives ( e.g. purines ) as protein kinases inhibitors | Astex Therapeutics Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| US-20100022564-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100022564-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (UK) | 2009-10-01 | — | — | US | disclosed |
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (UK) | 2009-10-01 | — | — | US | disclosed |
| CN-101489559-A | Purine and deazapurine derivatives as pharmaceutical compounds | ASTEX THERAPEUTICS LTD (GB) | 2009-07-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247538-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | CDK2, CDK1, OXSR1 | AKT1 388/4885AKT2 496/4885ROCK2 869/4885 |
| US-20140303177-A1 | ORTHO-CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E.G., PURINES) AS PROTEIN KINASES INHIBITORS | CDK2, CDK1, CDK3 | AKT1 476/4885AKT2 605/4885ROCK2 1041/4885 |
| US-20100022564-A1 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS | TPMT, CNKSR1, PRKD3 | AKT1 102/4885AKT2 126/4885ROCK2 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.